Compare EDUC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | CMMB |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | EDUC | CMMB |
|---|---|---|
| Price | $1.39 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 24.8K | ★ 84.0K |
| Earning Date | 01-08-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $25,371,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.02 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $1.60 |
| 52 Week High | $1.91 | $8.80 |
| Indicator | EDUC | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 33.76 |
| Support Level | $1.35 | $1.70 |
| Resistance Level | $1.58 | $1.85 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.14 | 22.50 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.